Invention Grant
- Patent Title: Lysyl oxidase inhibitors
-
Application No.: US16755739Application Date: 2018-10-12
-
Publication No.: US11325915B2Publication Date: 2022-05-10
- Inventor: Richard Marais , Caroline Springer , Dan Niculescu-Duvaz , Natalie Miller , Mohammed Aljarah , Alfonso Zambon , Leo Leung , Deborah Smithen , Michael Brown , Haoran Tang
- Applicant: The Institute of Cancer Research: Royal Cancer Hospital
- Applicant Address: GB London
- Assignee: The Institute of Cancer Research: Royal Cancer Hospital
- Current Assignee: The Institute of Cancer Research: Royal Cancer Hospital
- Current Assignee Address: GB London
- Agency: Foley Hoag LLP
- Agent David P. Halstead
- Priority: GB1716871 20171013
- International Application: PCT/GB2018/052934 WO 20181012
- International Announcement: WO2019/073251 WO 20190418
- Main IPC: C07D471/08
- IPC: C07D471/08 ; A61K31/439 ; A61P35/00 ; C07D487/08
Abstract:
This invention relates to compounds useful as lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family member (LOXL1, LOXL2, LOXL3, LOXL4) inhibitors. In addition there are contemplated pharmaceutical compositions comprising the compounds and the use of the compounds in the treatment of conditions mediated by LOX and LOXL, for example cancer. In particular a LOX inhibitor such as the present compounds may be for use in the treatment of a cancer associated with EGFR. The present invention also contemplates the identification of biomarkers that predict responsiveness to a LOX inhibitor.
Public/Granted literature
- US20200331922A1 LYSYL OXIDASE INHIBITORS Public/Granted day:2020-10-22
Information query
